Rx Product News (August 2017)

SEPTEMBER 05, 2017

ORENCIA
MARKETED BY
: Bristol-Myers Squibb
INDICATION: The FDA has approved Orencia (abatacept) to treat adults with active psoriatic arthritis in both intravenous and subcutaneous injection formulations.
DOSAGE FORM: IV: 250 mg; injection: 50 mg/ 0.4 mL, 87.5 mg/0.7 mL, 125 mg/mL in single-dose prefilled syringes, or 125 mg/mL in a single-dose prefilled ClickJect autoinjector.
FOR MORE INFORMATION: bms.com


COTEMPLA XR-ODT
MARKETED BY
: Neos Therapeutics
INDICATION: The FDA has approved Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets to treat attention-deficit/hyperactivity disorder in patients aged 6 to 7 years.
DOSAGE FORM: Extended-release orally disintegrating tablets: 8.6 mg, 17.3 mg, and 25.9 mg
FOR MORE INFORMATION: neostx.com


RITUXAN HYCELA
MARKETED BY
: Genentech
INDICATION: The FDA approved Genentech’s rituximab/hyaluronidase (Rituxan Hycela) combination treatment for adult patients with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia. DOSAGE FORM: Injection
FOR MORE INFORMATION: gene.com


ENDARI
MARKETED BY
: Emmaus Medical, Inc.
INDICATION: The FDA has approved Endari (L-glutamine oral powder) to reduce the severe complications of sickle cell disease in adult and pediatric patients 5 years and older. DOSAGE FORM: Oral powder
FOR MORE INFORMATION: emmausmedical.com

SHARE THIS SHARE THIS
1725
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.